Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Kalytera Therapeutics Inc. (KLY) completes name change to Claritas Pharmaceuticals, Inc
  • Kalytera’s ticker symbol will change as a result of the name change
  • The new ticker symbol will be CLAS, pending final approval of the TSX Venture Exchange
  • To hold an annual and special meeting on June 17, 2021
  • Kalytera Therapeutics (KYL) is down 11.11 per cent and is trading at C$0.040 at 11:29 am ET

Kalytera Therapeutics, Inc. (KLY) has changed its name to Claritas Pharmaceuticals, Inc.

The decision to rename Kalytera signals the re-launch of Kalytera.

It intends to focus on developing its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 and other viral infections.

R-107 is a nitric oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the viruses that cause influenza and the common cold.

Kalytera’s ticker symbol will change as a result of the name change.

The new ticker symbol will be CLAS, pending final approval of the TSX Venture Exchange, which is anticipated early next week.

Shareholders will receive letters of transmittal from the Kalytera transfer agent, which will also be posted on SEDAR, which can be used to exchange their current share certificates for certificates with Kalytera’s new name.

Shareholders holding shares in electronic form need not take any action.

All shareholders should refer to the letter of transmittal and instructions from their broker/dealer.

It also announced today that it is holding its annual and special meeting of shareholders on June 17, 2021.

The record date for the Meeting is April 28, 2021.

Only shareholders of record at the close of business on April 28, 2021, may vote at the meeting.

At the meeting, shareholders will be asked to vote on the election of directors, Kalytera’s auditors, and the renewal of Kalytera’s rolling 10 per cent stock option plan.

Claritas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Kalytera Therapeutics (KYL) is down 11.11 per cent and is trading at C$0.040 at 11:29 am ET.

More From The Market Herald

" BioHarvest Sciences (CSE:BHSC) appoints Steven Lehrer to its advisory board

BioHarvest Sciences (BHSC) has appointed Steven Lehrer as its newest advisory board member, effective immediately.

" CloudMD (TSXV:DOC) Receives U.S. patent approval

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

" NervGen Pharma (TSXV:NGEN) introduces Spinal Cord Injury Board

NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.
Medicenna Therapeutics Corp - CEO, Fahar Merchant

" Medicenna (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Medicenna Therapeutics (MDNA) has received FDA approval to expand the Phase 1/2 ABILITY study of MDNA11 to clinical trial sites in the US.